Vir hepatitis D drug succeeds in first pivotal study

A program that’s survived Vir’s pivot away from infectious disease research hit all of its study objectives and appeared more potent than a rival drug also in late-stage development.

By Delilah Alvarado • Nov. 9, 2026

Translating Phase II success into Phase III readiness takes more than scale

The move from Phase II to Phase III is often treated as a clinical milestone, when it is actually a development-wide transition.

Nov. 9, 2026

Explore the Trendline➔

Radiopharmaceuticals

A series of technological advances have led to an explosion of scientific progress — and dealmaking — involving medicines that can precisely deliver radioactive materials into tumors.   

By BioPharma Dive staff

At ASH, drugmakers to showcase early data for three-pronged cancer therapies

J&J and AbbVie are among the companies advancing “trispecific” antibodies that could become another step forward in treatment for multiple myeloma.

By Jonathan Gardner • Nov. 5, 2026

This week in charts: ESMO’s winners and losers

The latest installment in BioPharma Dive’s visualization-focused series looks at Wall Street’s response to a trio of closely watched presentations at a top meeting for cancer drugs.

By Jonathan Gardner • Oct. 30, 2026

Genmab soars to record highs after cancer drug succeeds in key trial

The drugmaker’s market value swelled by more than $7 billion on findings suggesting a recently-acquired medicine could become a new treatment standard for a form of head and neck cancer.

By Delilah Alvarado • Oct. 29, 2026

Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial

The highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher side effect rates and treatment discontinuations.

By Jonathan Gardner • Oct. 28, 2026

Court rejects Novo bid to block Lilly obesity drug ads

Novo failed to prove that Lilly’s campaign — which featured claims of obesity drug superiority — meaningfully harmed the Danish company’s sales, a federal judge ruled.

By Jonathan Gardner • Oct. 27, 2026

BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer study

The companies said the findings suggest the treatment has a “limited” impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo’s Enhertu has already set a high bar.

By Delilah Alvarado • Oct. 26, 2026

ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data

At one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share sell-off on Wall Street, while a lung drug received a standing ovation.

By Ben Fidler , Jonathan Gardner • Oct. 26, 2026

Moderna, Merck shares fall on eagerly anticipated cancer vaccine results

A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study that met Wall Street expectations but triggered a “sell-the-news reaction,” one analyst wrote.

By Jonathan Gardner • Oct. 22, 2026

Roivant, continuing ascent, claims another victory for rare disease drug

Shortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also be a “best-in-disease” medicine for an inflammatory eye condition, one analyst said.

By Kristin Jensen • Oct. 21, 2026

Rapport’s epilepsy drug finds surprising success in bipolar trial

Despite what some analysts described as low expectations, RAP-219 narrowly hit the main goal of a mid-stage study, results that could help it tap a billion-dollar-plus market opportunity.

By Jacob Bell • Oct. 20, 2026

Hype vs. reality: What pharma’s hottest R&D bets have actually proved

New types of bispecifics, antibody-drug conjugates and cell therapies haven’t yet proven themselves in the clinic. Pharmaceutical companies are betting billions anyway.

By Sy Mukherjee • Oct. 20, 2026

Disc’s once-spurned rare disease drug to get a second chance at approval

Months after the FDA rejected its treatment for a rare light-sensitivity disease, the biotech claimed success in a Phase 3 trial and now plans to re-engage regulators.

By Delilah Alvarado • Oct. 19, 2026

Experimental Arrowhead RNAi drug hints at Alzheimer’s benefit

In a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein implicated in the disease.

By Jonathan Gardner • Oct. 14, 2026

Verastem cancer drug shows early promise in small study

Wall Street analysts believe Verastem’s drug to now be “competitive” in what’s quickly become one of the most active and crowded areas of oncology research.

By Kristin Jensen • Oct. 14, 2026

BioNTech mRNA cancer immunotherapy misses first objective in key study

An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is holding out hope it might eventually extend survival.

By Delilah Alvarado • Oct. 13, 2026

First Tracks climbs on ‘impressive’ celiac study data

Initial study findings strengthened some analysts’ belief that First Tracks’ drug, one of a few in development aimed at the protein CD122, might have “pipeline-in-a-product” potential. 

By Delilah Alvarado • Oct. 12, 2026

Bristol Myers dips on ‘confounding’ lung drug results

Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, adding to analyst questions about the therapy’s prospects.

By Jonathan Gardner • Oct. 12, 2026

Argenx falls as Sjögren’s setback offsets celiac drug progress

A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ‘blockbuster expansion opportunity’ for Vyvgart. 

By Kristin Jensen • Oct. 8, 2026

A Takeda spinout builds case for its Parkinson’s drug

Cerevance plans to meet with the FDA to determine next steps for a new kind of medicine known as solengepras, now that it has Phase 3 data in hand.

By Jacob Bell • Oct. 7, 2026

ArriVent collapses on disappointing lung cancer data

More than half of the company’s value was wiped out by findings that appear to erase a chance to battle Johnson & Johnson and others for market share. 

By Delilah Alvarado • Oct. 6, 2026

Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial

The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.

By Jonathan Gardner • Oct. 6, 2026

[Podcast] (Season 2) The Progress Profile: Alzheimer’s Research in Focus

This podcast explores how leading Alzheimer’s experts are working to bridge the gap between clinical trial design and frontline care.

By BioPharma Dive's studioID • Oct. 6, 2026

Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data

The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer and Merck on nearly all bacterial strains in the first of three Phase 3 trials.

By Ben Fidler • Oct. 5, 2026